Amendment: SEC Form SC 13G/A filed by Avantor Inc.
$AVTR
Biotechnology: Laboratory Analytical Instruments
Industrials
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | $7.00 | Underperform | Wolfe Research |
| 5/15/2026 | $9.00 | Sector Perform | RBC Capital Mkts |
| 3/6/2026 | $8.50 | Equal Weight → Underweight | Barclays |
| 1/5/2026 | $12.00 | Outperform → In-line | Evercore ISI |
| 12/17/2025 | $9.00 | Hold → Underperform | Jefferies |
| 12/15/2025 | $13.00 | Buy → Neutral | BofA Securities |
| 11/4/2025 | Outperform → Mkt Perform | Raymond James | |
| 10/30/2025 | $12.00 | Overweight → Equal Weight | Barclays |
SD - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
10-Q - Avantor, Inc. (0001722482) (Filer)
Wolfe Research resumed coverage of Avantor with a rating of Underperform and set a new price target of $7.00
RBC Capital Mkts resumed coverage of Avantor with a rating of Sector Perform and set a new price target of $9.00
Barclays downgraded Avantor from Equal Weight to Underweight and set a new price target of $8.50
RADNOR, Pa., May 19, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Gerard (Jerry) Porreca has joined the company as Executive Vice President, Quality and Regulatory. In this role, Mr. Porreca is responsible for leading quality assurance, quality systems and regulatory affairs globally across all Avantor's businesses.Mr. Porreca is an accomplished executive with deep quality, regulatory affairs, and compliance experience
Net sales of $1,581 millionNet income of $43 million; Adjusted EBITDA of $219 millionDiluted GAAP EPS of $0.06; adjusted EPS of $0.17Operating cash flow of $59 million; free cash flow of $25 millionReaffirms FY 2026 guidanceRADNOR, Pa., April 29, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2026."First quarter results exceeded our expectations due to improved execution in Bioscience and Medtech Products, and we saw stabilization in VWR," said Emmanuel Ligner, President and Chi
RADNOR, Pa., April 23, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Ludovic Brellier will join the company as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer on May 1, 2026. In this role, Mr. Brellier will be responsible for growing the BMP business and improving operational performance. He will also lead the Revival Management Office, driving transformation initiatives acros
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire
RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately. Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in services, consumer and industrial end markets. Prior to founding Periphas, Mr. Mehra spent over 30 years at Goldman,
RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit
Net sales of $1,581 millionNet income of $43 million; Adjusted EBITDA of $219 millionDiluted GAAP EPS of $0.06; adjusted EPS of $0.17Operating cash flow of $59 million; free cash flow of $25 millionReaffirms FY 2026 guidanceRADNOR, Pa., April 29, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal quarter ended March 31, 2026."First quarter results exceeded our expectations due to improved execution in Bioscience and Medtech Products, and we saw stabilization in VWR," said Emmanuel Ligner, President and Chi
RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl
Revival program underway, including relaunch of VWR brand, implementation of critical manufacturing and supply chain improvements, and upgrades to e-commerce channel Fourth Quarter 2025 Net sales of $1.66 billion, decrease of 1%; organic decrease of 4%Net income of $52 million; Adjusted EBITDA of $252 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.22Operating cash flow of $153 million; free cash flow of $117 millionFull Year 2025 Net sales of $6.55 billion, decrease of 3%; organic decline of 3%Net loss of $530 million; Adjusted EBITDA of $1,069 millionDiluted GAAP loss per share of $0.78; adjusted EPS of $0.90Operating cash flow of $624 million; free cash flow of $496 millionRADNOR, Pa
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)